Piramal Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

By combining the innovative waste anaesthesia gas capture, collection, and processing technology developed by Blue-Zone, with the global manufacturing and marketing capabilities of Piramal, this collaboration will support customers? efforts to minimize the environmental impact of volatile anaesthetics.

This collaboration will also help ensure that these essential products remain the primary method of providing general anaesthesia for patients around the world.

Pending regulatory approval in Europe of Blue-Zone?s Phoenix Deltasorb waste anaesthetic gas capture system, Blue-Zone will offer these systems to PCC?s customers in Europe, initially in France and Germany.

Blue-Zone will be responsible for all activities involving the supply and use of its systems in healthcare facilities.

PCC will process captured waste anaesthetic gas using Blue Zone?s technology to produce Sevoflurane USP for human use in Canada.

The parties anticipate that the scope of the waste anaesthetic gas capture, collection and recycling, and the marketing of Sevoflurane USP using waste anaesthetic gas, will expand into additional geographies.

PCC is a global leader in anaesthesia, pain management and intrathecal therapy. PCC maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world.

Piramal Pharma offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries.

The company a consolidated net loss of Rs 136.19 crore in the quarter ended December 2025 as against net profit of Rs 3.68 crore during the previous quarter ended December 2024. Sales declined 2.92% to Rs 2139.87 crore in Q3 FY26 as compared with Q3 FY25.

The scrip shed 0.79% to currently trade at Rs 157.15 on the BSE.

Powered by Capital Market - Live News

Piramal Pharma announced the cessation of Subramanian Ramadorai (DIN: 00000002) as an independent director of the company with effect from 09 February 2026.

Powered by Capital Market - Live News

Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 159.5, up 3.6% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.16% on the day, quoting at 25302.45. The Sensex is at 82334.29, down 0.01%. Piramal Pharma Ltd has dropped around 6.89% in last one month.

Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has dropped around 4.57% in last one month and is currently quoting at 21739.85, down 1.06% on the day. The volume in the stock stood at 132.69 lakh shares today, compared to the daily average of 30.98 lakh shares in last one month.

The benchmark February futures contract for the stock is quoting at Rs 157.79, up 2.3% on the day. Piramal Pharma Ltd is down 31.03% in last one year as compared to a 8.83% gain in NIFTY and a 0.42% gain in the Nifty Pharma index.

The PE of the stock is 29.05 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

The board of Piramal Pharma at its meeting held on 28 January 2026 has approved the following change:

Resignation of Tanya Sanish as company secretary and compliance officer with effect from 20 February 2026.

Appointment of Pratibha Mishra (ACS No. 53432), as interim company secretary and compliance officer, KMP of the Company with effect from 21 February 2026.

Powered by Capital Market - Live News